INHIXA is a brand name for enoxaparin sodium, a type of anticoagulant medication commonly used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It belongs to a class of drugs known as low molecular weight heparins (LMWHs). INHIXA works by inhibiting certain factors in the blood coagulation process, effectively reducing the likelihood of blood clots forming in the veins. It is administered via subcutaneous injection and is often prescribed for patients undergoing surgeries, especially hip or knee replacement surgery, as well as for those who are at an increased risk of thromboembolic events due to prolonged immobilization or certain medical conditions. The use of INHIXA requires careful monitoring by healthcare professionals to ensure the correct dosage is administered and to minimize the risk of potential side effects, such as bleeding.